New clot-busting treatment targets number one killer

August 4, 2015 by Anne Rahilly, University of Melbourne
New clot-busting treatment targets number one killer
Nanotechnology developed to help treat heart attack and stroke.

Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.

The research jointly lead by Professor Christoph Hagemeyer, Head of the Vascular Biotechnology Laboratory at Baker IDI Heart and Diabetes Institute and Professor Frank Caruso, an ARC Australian Laureate Fellow in the Department of Chemical and Biomolecular Engineering at the University of Melbourne, was published today in the leading journal Advanced Materials.

Professor Hagemeyer said this latest step offers a revolutionary difference between the current treatments for clots and what might be possible in the future.

This life saving treatment could be administered by paramedics in emergency situations without the need for specialised equipment as is currently the case.

"We've created a nanocapsule that contains a clot-busting drug. The drug-loaded nanocapsule is coated with an antibody that specifically targets activated platelets, the cells that form ," Professor Hagemeyer said.

"Once located at the site of the blood clot, thrombin (a molecule at the centre of the clotting process) breaks open the outer layer of the nanocapsule, releasing the clot-busting drug. We are effectively hijacking the blood clotting system to initiate the removal of the blockage in the blood vessel," he said.

Professor Frank Caruso from the Melbourne School of Engineering said the targeted drug with its novel delivery method can potentially offer a safer alternative with fewer side effects for people suffering a heart attack or stroke.

"Up to 55,000 Australians experience a or suffer a stroke every year."

"About half of the people who need a clot-busting can't use the current treatments because the risk of serious bleeding is too high," he said.

Explore further: New treatments for blood clots on horizon

Related Stories

Study finds no net benefit from common anti-clotting drug

June 25, 2015

A costly drug frequently used to treat patients with heart disease may offer no greater benefit than standard medications, say Yale researchers. Their study calls into question widespread use of the drug bivalirudin (Angiomax) ...

Recommended for you

Bright colors produced by laser heating

January 15, 2019

Most of the colors on today's paper and fabric are made using dyes or pigments. But colors can also be produced by modifying a material's surface at the nanoscale, causing the surface to reflect or scatter different frequencies ...

Pore size influences nature of complex nanostructures

January 15, 2019

Building at the nanoscale is not like building a house. Scientists often start with two-dimensional molecular layers and combine them to form complex three-dimensional architectures. And instead of nails and screws, these ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.